On June 25, 2018, the U.S. Food and Drug Administration (FDA) announced its first-ever approval of a marijuana-derived pharmaceutical drug.
On August 11, 1930, Harry Jacob Anslinger became the director of the newly formed Federal Bureau of Narcotics (FBN) in Washington, D.C. The Voldemort of vipers, he would run the FBN with an iron fist through six presidential administrations spanning more than three decades.
Kratom is an unique medicinal herb with pain relieving properties that function as an opiate substitute. So why is the FDA and the DEA trying to block people’s access to it by making it a Schedule 1 drug?
Huge interest in the medicinal potential of CBD has catalyzed a rebirth of industrial hemp in the U.S. But is hemp the best source of CBD?
Several Cannabis-related bills have been introduced by the U.S. Congress in the current 114th Session. Three of these relate specifically to CBD.
Numerous commercial start-ups have jumped on the CBD bandwagon. But along with a growing awareness of CBD as a potential health aid there has been a proliferation of misconceptions.
How did it happen that a medical marijuana ballot initiative supported by almost 90% of Florida voters in the spring was defeated in November? Let us count the ways. “Our state is not providing the structure and safe access that we need to help our children. It is very frustrating.”